Redeye comments on Cinclus Pharma’s announcement earlier today of a EUR220m licensing agreement with...
Redeye comments on the intriguing data from the phase I/II CARMA-study presented by Elicera this mor...
Redeye comments on Jumpgate’s Q1 2025 report, which contained no major surprises and delivered a top...
Redeye shares its initial take on Genovis following the Q1 report, which delivered sales 13% above o...
Redeye comments on Embracer’s Q4-results which saw stronger-than-expected EBIT, driven by PC/Console...
Redeye comments on Better Collective’s Q1-results which were somewhat better than expected as revenu...
Q1 miss mainly driven by FK and SDR Cutting '25e EBITDA/EBIT by 9/15%, small changes to '26e-'27e FV...
Fiskars hosted its "Get to know Vita" day today. The company has been building its "brand first" app...
Redeye comments on Flexion Mobile's Q1 2025 report, which was pretty much in line with expectations.
Redey comments on Oncopeptides’ first quarter report 2025.
För det första kvartalet 2025 var intäkterna 39 procent lägre än Mangolds prognos.
Redeye returns with a more in-depth take on the Q1 earnings.
Redeye provides a brief comment on Kancera’s update regarding the collaboration with Recardio and th...
Underliggande tillväxt trots svagare kvartal Det första kvartalet var sammantaget svagare än motsva...
Redeye reiterates its fair value range following Dala Energi’s Q1 report that was published last Fri...
